NZC

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Nzuri Copper Limited

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Nzuri Copper Limited

πŸ“ˆ Performance

Price History

-100.00%

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in NZC

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in NZC

N/A
NZC investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in NZC also invest in...

Want more shares? Try these...

New Zealand King Salmon Investments Limited

NZK

New Zealand King Salmon Investments Ltd. is a holding company, which engages in the farming, processing and sale of salmon products. The company is headquartered in Nelson, Nelson. The company went IPO on 2016-10-19. The company is an aquaculture producer of the king salmon species. The Company’s brands include Ora King, Regal, Southern Ocean, and Omega Plus, and the New Zealand King Salmon label. Ora King has a vibrant flesh color and high fat content. Regal Marlborough King Salmon includes healthy omega-3 fatty acids, it is available in a wide variety of fresh salmon cuts, as well as convenient ready to cook options. Ora King products include Ora King Whole Fish, Ora King Fillet, Ora King Cold Smoked Fillet, and Ora King Cold Smoked Specialty Packs. Its range of smoked salmon products includes cold smoked slices and wood roasted fillets. Southern Ocean offers a range of packed smoked salmon products. The Omega Plus pet food range offers a complete diet to maintain the health and well-being of the pets. The company offers treats and supplements.

πŸ™Œ Performance (5Yr p.a)

-18.02%

πŸ“Š Share price

$0.20 AUD

πŸ” FOOD PRODUCTS

Find Out More

Nyrada, Inc. is a pre-clinical stage, drug discovery, and development company, which engages in the business of specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.

πŸ™Œ Performance (5Yr p.a)

-9.51%

πŸ“Š Share price

$0.10 AUD

πŸ“¦ LOGISTICS